ArticleCureus2026
Association of an Accelerated High-Sensitivity Cardiac Troponin-Anchored Care Pathway With 30-Day Mortality and Intensive Care Outcomes in Acute Coronary Syndrome: A Retrospective Cohort Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute coronary syndrome causes substantial short-term mortality, cardiovascular complications, and intensive care use. High-sensitivity cardiac troponin within an accelerated care pathway may support earlier recognition and management.
objectiveTo assess the association between an accelerated high-sensitivity cardiac troponin-anchored care pathway and 30-day mortality and intensive care outcomes in acute coronary syndrome.
methodsThis retrospective cohort study was conducted at the Department of Internal Medicine, University at Buffalo, New York, from April 2024 to April 2025. Records of 200 patients were reviewed: 100 managed through the accelerated pathway and 100 receiving standard care. The pathway was defined as definitive clinical action within three hours based on troponin findings, clinical assessment, and electrocardiography. The primary outcome was 30-day all-cause mortality; secondary outcomes were exploratory.
resultsMeasured baseline characteristics did not differ significantly. Time to definitive decision was shorter with the accelerated pathway (2.1 ± 0.6 vs. 5.7 ± 1.8 hours; p<0.001). Thirty-day mortality was 7.0% vs. 16.0%, with an absolute risk difference of -9.0 percentage points (95% confidence interval: -17.8 to -0.2; p=0.046). Acute heart failure, malignant arrhythmias, cardiogenic shock, intensive care unit admission, and hospital stay were lower in exploratory unadjusted analyses. Exploratory multivariable analysis showed an association with lower 30-day mortality (adjusted odds ratio: 0.40; 95% confidence interval: 0.16-0.98; p=0.045).
conclusionThe accelerated pathway was associated with lower observed mortality and fewer short-term complications. Causal conclusions cannot be drawn because of the retrospective, non-randomized design and potential residual confounding.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.